Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octanorm in patients with dermatomyositis
ISRCTN11520709Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Octanorm with Placebo (2 arms). Primary endpoints: Muscle strength by MMT-8, Cutaneous disease activity by CDASI and 1 more. Started Aug 2018; status: terminated.
02
Drugs
Nanogam
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on ISRCTN11520709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11520709.